- In patients with acute ischaemic stroke (AIS) and intracranial atherosclerotic disease (ICAD), high-dose statin therapy effectively stabilises symptomatic intracranial atherosclerotic plaques on serial high-resolution magnetic resonance imaging (HR-MRI) at 6 months.
Why this matters
- Pre-stroke statin use has been reported to modify plaque enhancement in symptomatic intracranial atherosclerosis.
- However, limited evidence exists over the long-term effects of high-dose statin treatment on the stabilisation of vulnerable intracranial plaques.
- The Intensive Statin Treatment in Acute Ischaemic Stroke Patients with Intracranial Atherosclerosis – HR-MRI (STAMINA-MRI), a single arm observational study included 77 patients with AIS and ICAD on high dose statin therapy.
- Primary outcomes: changes in stenosis degree, remodelling and wall area index and enhancement volume of atherosclerotic plaque on HR-MRI before and after 6 months of statin therapy.
- Funding: Samsung Medical Center and Dong-A Pharma, Inc. Seoul, South Korea.
- After 6 months of follow-up, high-dose statin therapy significantly reduced:
- total cholesterol (123.20±24.53 mg/dL; P<.001>
- triglyceride (121.85±53.28 mg/dL; P=.003),
- low-density lipoprotein cholesterol (LDL-C; 60.95±19.28 mg/dL; P<.001>
- non-high-density lipoprotein cholesterol (73.7±21.0 mg/dL; P<.001 and>
- apolipoprotein B (63.73±16.73; P<.001>
- Single-centre study with a small sample size.
- Significant variation in the time interval between initial and follow-up HR-MRIs.